CGS-20625

Source: Wikipedia, the free encyclopedia.
CGS-20625
Clinical data
Routes of
administration		By mouth
ATC code
  • none
Pharmacokinetic data
Bioavailability41%
Identifiers
  • 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
JSmol)
  • COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2
  • InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3 ☒N
  • Key:UBLXQFIFWUEVGJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs,[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[2][3] It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects.[4] It is orally active in humans, but with relatively low bioavailability.[5]

CGS-20625 is a

alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines.[1] γ1 subunits are expressed at higher levels in the central amygdala.[6]

References

  1. ^
    S2CID 15082432
    .
  2. S2CID 45892825
    .
  3. PMID 1686029
    .
  4. PMID 2563294
    .
  5. S2CID 22126140
    .
  6. S2CID 1590604
    .


Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CGS-20625&oldid=1189134303"